<DOC>
	<DOCNO>NCT00312143</DOCNO>
	<brief_summary>This trial design assess efficacy , tolerability , safety EC-MPS combination cyclosporine microemulsion ( CsA-ME ) without steroid kidney transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Enteric-coated Mycophenolate Sodium ( EC-MPS ) de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion 1 . Males female age 18 75 year . 2 . Recipients live related kidney transplant , treat cyclosporine , without corticosteroid , primary immunosuppression . 3 . Females childbearing potential must negative serum pregnancy test within 7 day prior screen . Effective contraception must use trial , 6 week follow discontinuation study medication , even history infertility . 4 . Patients willing able participate full course study write informed consent obtain . Exclusion criterion : 1 . Multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ , kidney . 2 . Patients know hypersensitivity component formulation ( e.g . lactose ) . 3 . Patients low platelet count ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 , and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6 g/dL screen baseline . 4 . Patients receive investigational drug within four week prior study entry . 5 . Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin . 6 . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>De novo Kidney Transplant recipient , enteric-coated mycophenolate sodium</keyword>
</DOC>